Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101.
暂无分享,去创建一个
Wolfhard Semmler | Fabian Kiessling | Stefan Delorme | Peter Bohlen | Matthias P Lichy | S. Delorme | W. Semmler | N. Fusenig | P. Bohlen | F. Kiessling | Silvia Vosseler | M. Heilmann | M. Lichy | M. Krix | Melanie Heilmann | Norbert E Fusenig | Silvia Vosseler | Margareta M Mueller | Martin Krix | Nabeel Farhan | Dan W Miller | N. Farhan | M. Mueller | Daniel W Miller | P. Bőhlen
[1] Fabian Kiessling,et al. Comparing Dynamic Parameters of Tumor Vascularization in Nude Mice Revealed by Magnetic Resonance Imaging and Contrast‐Enhanced Intermittent Power Doppler Sonography , 2003, Investigative radiology.
[2] Robert C Brasch,et al. Dynamic contrast‐enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti‐angiogenic therapy in a xenograft model of glioblastoma multiforme , 2002, Journal of magnetic resonance imaging : JMRI.
[3] Weissleder,et al. Approaches and agents for imaging the vascular system. , 1999, Advanced drug delivery reviews.
[4] J. Folkman,et al. Angiogenesis-dependent diseases. , 2001, Seminars in oncology.
[5] H. Lyng,et al. Measurement of perfusion rate in human melanoma xenografts by contrast‐enhanced magnetic resonance imaging , 1998, Magnetic resonance in medicine.
[6] W. J. Lorenz,et al. Pharmacokinetic Mapping of the Breast: A New Method for Dynamic MR Mammography , 1995, Magnetic resonance in medicine.
[7] G Brix,et al. Multicompartment analysis of gadolinium chelate kinetics: Blood‐tissue exchange in mammary tumors as monitored by dynamic MR imaging , 1999, Journal of magnetic resonance imaging : JMRI.
[8] G. van Kaick,et al. Bone marrow microcirculation analysis in multiple myeloma by contrast‐enhanced dynamic magnetic resonance imaging , 2001, International journal of cancer.
[9] D Artemov,et al. Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. , 2001, Neoplasia.
[10] J. Garlick,et al. Tumor progression of skin carcinoma cells in vivo promoted by clonal selection, mutagenesis, and autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. , 2001, The American journal of pathology.
[11] D M Shames,et al. MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. , 2001, Radiology.
[12] Rakesh K. Jain,et al. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.
[13] A R Padhani,et al. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. , 2001, Clinical radiology.
[14] T. Helbich,et al. Prostate cancer tumor grade differentiation with dynamic contrast-enhanced MR imaging in the rat: comparison of macromolecular and small-molecular contrast media--preliminary experience. , 1999, Radiology.
[15] J. Minna,et al. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. , 2000, Cancer research.
[16] J. Folkman. Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.
[17] M V Knopp,et al. Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[18] J. Fox,et al. The mouse in biomedical research. Volume III. Normative biology, immunology, and husbandry. , 1983 .
[19] M. Neeman,et al. Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis. , 1999, Neoplasia.
[20] S. Baruchel,et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. , 2000, The Journal of clinical investigation.
[21] P. Agre,et al. Aquaporins and the respiratory system: advice for a lung investigator. , 2000, The Journal of clinical investigation.
[22] M. Décorps,et al. Vessel size imaging , 2001, Magnetic resonance in medicine.
[23] G. Gasparini,et al. Metronomic scheduling: the future of chemotherapy? , 2001, The Lancet. Oncology.
[24] G. Neufeld,et al. Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[25] L. Schad,et al. Dynamic T1‐weighted monitoring of vascularization in human carcinoma heterotransplants by magnetic resonance imaging , 2003, International journal of cancer.
[26] R Weissleder,et al. Size optimization of synthetic graft copolymers for in vivo angiogenesis imaging. , 2001, Bioconjugate chemistry.
[27] R. Kerbel. Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.
[28] M. Neeman,et al. Neovascularization induced growth of implanted C6 glioma multicellular spheroids: magnetic resonance microimaging. , 1995, Cancer research.
[29] L R Schad,et al. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. , 1991, Journal of computer assisted tomography.
[30] N. Fusenig,et al. Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes , 1998, Molecular carcinogenesis.
[31] F. Scappaticci. Mechanisms and future directions for angiogenesis-based cancer therapies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Mihaela Skobe,et al. Halting angiogenesis suppresses carcinoma cell invasion , 1997, Nature Medicine.
[33] Alan Jackson,et al. Dynamic contrast-enhanced magnetic resonance imaging in oncology , 2005 .
[34] S. Fox,et al. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. , 2001, The Lancet. Oncology.
[35] Fabian Kiessling,et al. Sensitive noninvasive monitoring of tumor perfusion during antiangiogenic therapy by intermittent bolus-contrast power Doppler sonography. , 2003, Cancer research.
[36] M. Bock,et al. Magnetic Resonance Imaging of Nude Mice With Heterotransplanted High-Grade Squamous Cell Carcinomas: Use of a Low-Loaded, Covalently Bound Gd-Hsa Conjugate as Contrast Agent With High Tumor Affinity , 2002, Investigative radiology.
[37] N. van Bruggen,et al. Assessing tumor angiogenesis using macromolecular MR imaging contrast media , 1997, Journal of magnetic resonance imaging : JMRI.
[38] 久場 敬司. HGF/NK4,a Four-Kringle Antagonist of Hepatocyte Growth Factor,Is an Angiogenesis Inhibitor that Suppresses Tumor Growth and Metastasis in Mice , 2001 .
[39] M. Knopp,et al. Cervical carcinoma: standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. , 1999 .
[40] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[41] M. Dewhirst,et al. Magnetic resonance imaging applications in the evaluation of tumor angiogenesis. , 2001, Seminars in radiation oncology.
[42] K. Thomas. Vascular Endothelial Growth Factor, a Potent and Selective Angiogenic Agent (*) , 1996, The Journal of Biological Chemistry.
[43] G. Yancopoulos,et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.